<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92574">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121054</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0873</org_study_id>
    <nct_id>NCT02121054</nct_id>
  </id_info>
  <brief_title>Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease</brief_title>
  <official_title>Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Young-Hak Kim, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the prognosis of patients with resistance to
      antiplatelet agent and develop tailored treatment model for patients with coronary artery
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Major adverse event</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major adverse event : overall mortality, cardiovascular mortality, target vessel revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>homocysteine, Lp(a), fibrinogen, PAI-1, NTpro-BNP, hs-CRP, matrix metalloproteinase-9, soluble CD40L, IL-6, serum amyloid A, AGE</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ã€‰20

          -  Patients with coronary artery disease

        Exclusion Criteria:

          -  Renal dysfunction

          -  Hepatic dysfunction

          -  Major surgery planned within 1 year

          -  Malignant tumor

          -  History of gastrointestinal bleeding

          -  low or high platelet count
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hak Kim, MD, PhD</last_name>
      <phone>82-2-3010-3955</phone>
      <email>mdyhkim@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Hak Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Hak Kim, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Antiplatelet Agents</keyword>
  <keyword>Drug Resistance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
